791 related articles for article (PubMed ID: 18998069)
1. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
2. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.
Zhou M; Learned RM; Rossi SJ; DePaoli AM; Tian H; Ling L
Hepatology; 2016 Mar; 63(3):914-29. PubMed ID: 26418580
[TBL] [Abstract][Full Text] [Related]
3. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
4. Effect of mdr2 mutation with combined tandem disruption of canalicular glycoprotein transporters by cyclosporine A on bile formation in mice.
Elamiri A; Perwaiz S; Tuchweber B; Yousef IM
Pharmacol Res; 2003 Nov; 48(5):467-72. PubMed ID: 12967592
[TBL] [Abstract][Full Text] [Related]
5. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
Halilbasic E; Fiorotto R; Fickert P; Marschall HU; Moustafa T; Spirli C; Fuchsbichler A; Gumhold J; Silbert D; Zatloukal K; Langner C; Maitra U; Denk H; Hofmann AF; Strazzabosco M; Trauner M
Hepatology; 2009 Jun; 49(6):1972-81. PubMed ID: 19475687
[TBL] [Abstract][Full Text] [Related]
6. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects.
Davit-Spraul A; Gonzales E; Baussan C; Jacquemin E
Semin Liver Dis; 2010 May; 30(2):134-46. PubMed ID: 20422496
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
[TBL] [Abstract][Full Text] [Related]
8. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.
Liu T; Yang H; Fan W; Tu J; Li TWH; Wang J; Shen H; Yang J; Xiong T; Steggerda J; Liu Z; Noureddin M; Maldonado SS; Annamalai A; Seki E; Mato JM; Lu SC
Gastroenterology; 2018 Aug; 155(2):557-571.e14. PubMed ID: 29733835
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of cholestatic liver diseases].
Gatzen M; Pausch J
Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
[TBL] [Abstract][Full Text] [Related]
12. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
13. A female of progressive familial intrahepatic cholestasis type 3 caused by heterozygous mutations of ABCB4 gene and her cirrhosis improved after treatment of ursodeoxycholic acid: a case report.
Qiao F; Ren F; Lu W; Yang H; Mo G; Wang S; Liu L; Xu X
BMC Med Genomics; 2023 Jul; 16(1):171. PubMed ID: 37488596
[TBL] [Abstract][Full Text] [Related]
14. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes.
Trauner M; Fickert P; Wagner M
Semin Liver Dis; 2007 Feb; 27(1):77-98. PubMed ID: 17295178
[TBL] [Abstract][Full Text] [Related]
15. Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
Stättermayer AF; Halilbasic E; Wrba F; Ferenci P; Trauner M
J Hepatol; 2020 Sep; 73(3):651-663. PubMed ID: 32376413
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
Pusl T; Beuers U
World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
[TBL] [Abstract][Full Text] [Related]
17. Metabolic preconditioning protects BSEP/ABCB11
Fuchs CD; Paumgartner G; Wahlström A; Schwabl P; Reiberger T; Leditznig N; Stojakovic T; Rohr-Udilova N; Chiba P; Marschall HU; Trauner M
J Hepatol; 2017 Jan; 66(1):95-101. PubMed ID: 27593105
[TBL] [Abstract][Full Text] [Related]
18. ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression.
Degiorgio D; Crosignani A; Colombo C; Bordo D; Zuin M; Vassallo E; Syrén ML; Coviello DA; Battezzati PM
J Gastroenterol; 2016 Mar; 51(3):271-80. PubMed ID: 26324191
[TBL] [Abstract][Full Text] [Related]
19. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis.
Fickert P; Stöger U; Fuchsbichler A; Moustafa T; Marschall HU; Weiglein AH; Tsybrovskyy O; Jaeschke H; Zatloukal K; Denk H; Trauner M
Am J Pathol; 2007 Aug; 171(2):525-36. PubMed ID: 17600122
[TBL] [Abstract][Full Text] [Related]
20. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis.
Trauner M; Wagner M; Fickert P; Zollner G
J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S111-24. PubMed ID: 15758646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
